Table 3.
Treatments and outcomes of patients infected with 2019-nCoV
| All patients (n=41) | ICU care (n=13) | No ICU care (n=28) | p value | ||
|---|---|---|---|---|---|
| Duration from illness onset to first admission | 7·0 (4·0–8·0) | 7·0 (4·0–8·0) | 7·0 (4·0–8·5) | 0·87 | |
| Complications | |||||
| Acute respiratory distress syndrome | 12 (29%) | 11 (85%) | 1 (4%) | <0·0001 | |
| RNAaemia | 6 (15%) | 2 (15%) | 4 (14%) | 0·93 | |
| Cycle threshold of RNAaemia | 35·1 (34·7–35·1) | 35·1 (35·1–35·1) | 34·8 (34·1–35·4) | 0·35 | |
| Acute cardiac injury* | 5 (12%) | 4 (31%) | 1 (4%) | 0·017 | |
| Acute kidney injury | 3 (7%) | 3 (23%) | 0 | 0·027 | |
| Secondary infection | 4 (10%) | 4 (31%) | 0 | 0·0014 | |
| Shock | 3 (7%) | 3 (23%) | 0 | 0·027 | |
| Treatment | |||||
| Antiviral therapy | 38 (93%) | 12 (92%) | 26 (93%) | 0·46 | |
| Antibiotic therapy | 41 (100%) | 13 (100%) | 28 (100%) | NA | |
| Use of corticosteroid | 9 (22%) | 6 (46%) | 3 (11%) | 0·013 | |
| Continuous renal replacement therapy | 3 (7%) | 3 (23%) | 0 | 0·027 | |
| Oxygen support | .. | .. | .. | <0·0001 | |
| Nasal cannula | 27 (66%) | 1 (8%) | 26 (93%) | .. | |
| Non-invasive ventilation or high-flow nasal cannula | 10 (24%) | 8 (62%) | 2 (7%) | .. | |
| Invasive mechanical ventilation | 2 (5%) | 2 (15%) | 0 | .. | |
| Invasive mechanical ventilation and ECMO | 2 (5%) | 2 (15%) | 0 | .. | |
| Prognosis | .. | .. | .. | 0·014 | |
| Hospitalisation | 7 (17%) | 1 (8%) | 6 (21%) | .. | |
| Discharge | 28 (68%) | 7 (54%) | 21 (75%) | .. | |
| Death | 6 (15%) | 5 (38%) | 1 (4%) | .. | |
Data are median (IQR) or n (%). p values are comparing ICU care and no ICU care. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit. NA=not applicable. ECMO=extracorporeal membrane oxygenation.
*
Defined as blood levels of hypersensitive troponin I above the 99th percentile upper reference limit (>28 pg/mL) or new abnormalities shown on electrocardiography and echocardiography.